Musto P - Search Results

1

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangiolosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hájek R, Boccadoro M, Bringhen S. Larocca A, et al. Among authors: musto p. Haematologica. 2020 Apr;105(4):1074-1080. doi: 10.3324/haematol.2019.220657. Epub 2019 Jun 27. Haematologica. 2020. PMID: 31248973 Free PMC article. Clinical Trial.

2

Nodular lesions of the liver in multiple myeloma: a role for cytoadhesion molecules?

Musto P, Falcone A, Caturelli E, Squillante MM, Castelvetere M, Carotenuto M. Musto P, et al. Tumori. 1992 Oct 31;78(5):300-4. doi: 10.1177/030089169207800504. Tumori. 1992. PMID: 1283646

3

[Glycoprotein P-170, associated with multidrug resistance, in patients with acute leukemia in complete remission].

Musto P, Carotenuto M. Musto P, et al. Haematologica. 1991 Jun;76 Suppl 3:169-72. Haematologica. 1991. PMID: 1684343 Italian. No abstract available.

4

The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma.

Musto P, Lombardi G, Matera R, Carotenuto M. Musto P, et al. Haematologica. 1991 Nov-Dec;76(6):513-6. Haematologica. 1991. PMID: 1687943

5

Treatment of plasma cell leukaemia and resistant/relapsed multiple myeloma with vincristine, mitoxantrone and dexamethasone (VMD protocol).

Musto P, Greco MM, Falcone A, Carotenuto M. Musto P, et al. Br J Haematol. 1991 Dec;79(4):655-6. doi: 10.1111/j.1365-2141.1991.tb08101.x. Br J Haematol. 1991. PMID: 1772791 No abstract available.

6

Serum C-reactive protein and infections in malignant hematological disorders.

Musto P, Falcone A, La Sala A, Cascavilla N, Carotenuto M. Musto P, et al. Haematologica. 1990 Sep-Oct;75(5):492-3. Haematologica. 1990. PMID: 2097276 No abstract available.

7

Thymidine kinase in neoplastic haematological diseases: confirmations, doubts and new findings.

Musto P, Longo S, Morelli A, Ficola U, Falcone A, Carotenuto M. Musto P, et al. Haematologica. 1988 Nov-Dec;73(6):545-6. Haematologica. 1988. PMID: 3148519 No abstract available.

8

Misleading cytogenetic evidence of relapse in donor cells after allogeneic bone marrow transplantation corrected by fluorescent in situ hybridization.

Perla G, Bodenizza C, Falcone A, Melillo L, Scolaro E, Carotenuto M, Musto P. Perla G, et al. Among authors: musto p. Haematologica. 1995 May-Jun;80(3):292-3. Haematologica. 1995. PMID: 7672724 No abstract available.

9

Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.

Musto P, Modoni S, Alicino G, Savino A, Longo A, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, et al. Musto P, et al. Haematologica. 1994 Nov-Dec;79(6):493-9. Haematologica. 1994. PMID: 7896207

10

Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.

Musto P, Matera R, Minervini MM, Checchia-de Ambrosio C, Bodenizza C, Falcone A, Carotenuto M. Musto P, et al. Haematologica. 1994 May-Jun;79(3):265-8. Haematologica. 1994. PMID: 7926977 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

646 results

Search Page

Filters